TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15463836

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled colistin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS) and Inhaled colistin
Number of subjects: 0
Study: 10071997

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.1 microg x kg(‐1) x min(‐1) and saline bolus (5 mL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Saline infusion and remifentanil bolus (25 microg in 5 mL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.05 microg x kg(‐1) x min(‐1) and remifentanil bolus (12.5 microg in 5 mL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Variable-rate continuous infusion of remifentanil
Number of subjects: 45
Study: 7585853

Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 260

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Enoxacin and TMP-SMX
Number of subjects: 260
Study: 2342129

Group type: EXPERIMENTAL
Intervention: Sodium sulfate (4 g/day for 14 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sodium sulfate
Number of subjects: 57
Study: 6108607

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 100 mg (89.4 mg of ranitidine base) twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (open treatment)
Number of subjects: 49
Study: 31150662

Group type: EXPERIMENTAL
Intervention: Lifting phase (light and heavy objects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holding phase (light and heavy objects)
Number of subjects: 0
Study: 27992099

Group type: EXPERIMENTAL
Intervention: Supervised home-based telerehabilitation (TG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care without exercise training (CG)
Number of subjects: 36
Study: 25913479

Group type: EXPERIMENTAL
Intervention: AML-BFM 04 treatment protocol
Number of subjects: 97

Group type: COMPARATOR
Intervention: AML-BFM 98 treatment protocol
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation in first remission
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gain of chromosome 21
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Translocation t(1;22)(p13;q13)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Treatment response (bone marrow morphology on day 15 and 28)
Number of subjects: 97
Study: 23539081

Group type: EXPERIMENTAL
Intervention: Training on a motorized, polyethylene high-resistance flywheel for 9 sessions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Training on ice for 9 sessions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects who did not practice crossovers
Number of subjects: 23
Study: 21413548

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19791705

Group type: EXPERIMENTAL
Intervention: Safe Delivery Incentive Programme (SDIP) cash transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No women's groups
Number of subjects: 0
Study: 17538878

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 80
Study: 15031350

Group type: EXPERIMENTAL
Intervention: pH‐neutral low‐GDP solution (Balance)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional solution (S‐PDF)
Number of subjects: 17
Study: 11840198

Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) package
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional teaching (20 min mini-lecture)
Number of subjects: 48
Study: 9725758

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg, orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual task condition (visual discrimination task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resource depletion hypothesis
Number of subjects: 0
Study: 8000101

Group type: EXPERIMENTAL
Intervention: Selegiline (L-deprenyl) at a dose of 7.5 mg/day (Group D, n = 60)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (Group P, n = 52)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Selegiline (L-deprenyl) (Group D)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 112
Study: 2647130

Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg three times daily, increasing to 200 mg three times daily where required)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: COMPARATOR
Intervention: Labetalol and Placebo
Number of subjects: 152
Study: 1092285

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 64
Study: 31736189

Group type: EXPERIMENTAL
Intervention: Algorithm for identifying MGUS cases using electronic health data.
Number of subjects: 833
Study: 31168802

Group type: EXPERIMENTAL
Intervention: Subcutaneous crenezumab (300mg) every 2 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intravenous crenezumab (15mg/kg) every 4 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 28683829

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 26489055

Group type: EXPERIMENTAL
Intervention: Operative repair with hook plate fixation
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 83
Study: 23369412

Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn (10^11 viral particles)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn (all doses combined)
Number of subjects: 166
Study: 21452293

Group type: EXPERIMENTAL
Intervention: Atacicept (25 mg, 75 mg, or 150 mg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 17562086

Group type: EXPERIMENTAL
Intervention: Support-group intervention (for 11 CT-RT and 10 RT patients)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (remaining patients not receiving support intervention)
Number of subjects: 41
Study: 16606972

Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel (T) added to doxorubicin and cyclophosphamide (AC)
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel (T)
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Postoperative docetaxel (T)
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Addition of T to AC
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Pathologic nodal status after chemotherapy
Number of subjects: 2411
Study: 12488303

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², 3-weekly cycles, up to 3 cycles)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m²)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 274
Study: 11826920

Group type: EXPERIMENTAL
Intervention: Pivot drawer test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flexion rotation drawer test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Slocum test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lachman test
Number of subjects: 100

Group type: COMPARATOR
Intervention: KT‐1000 knee ligament arthrometer
Number of subjects: 100
Study: 9087387

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) therapy
Number of subjects: 50
Study: 1438493

Group type: EXPERIMENTAL
Intervention: Pentobarbital (150 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3515952

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 70
Study: 30430635

Group type: EXPERIMENTAL
Intervention: Face-to-face group (FG) attending 12 Go group lessons once a week
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-face-to-face group (NFG) using a tablet for the same Go lessons
Number of subjects: 72

Group type: COMPARATOR
Intervention: Health education control group (CG)
Number of subjects: 72
Study: 29250907

Group type: EXPERIMENTAL
Intervention: Genome sequencing for preconception carrier screening
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (single disease carrier testing)
Number of subjects: 51
Study: 26811534

Group type: EXPERIMENTAL
Intervention: CELF4 rs1786814 GG genotype with anthracycline exposure > 300 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CELF4 rs1786814 GG genotype
Number of subjects: 0
Study: 25268802

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg or higher
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 22791245

Group type: EXPERIMENTAL
Intervention: Test formulation of 50 mg atenolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of 50 mg atenolol
Number of subjects: 24
Study: 19460188

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 943
Study: 17363758

Group type: EXPERIMENTAL
Intervention: Entity theorists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit theories of groups manipulated via instruction set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of group entitativity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit theory
Number of subjects: 0
Study: 12204875

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control device (inactive oral appliance)
Number of subjects: 73
Study: 10037433

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride per day for 6 months
Number of subjects: 0
Study: 8791113

Group type: EXPERIMENTAL
Intervention: Complex antioxidant treatment for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet rich in fresh fruits and vegetables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidants with or without H. pylori eradication
Number of subjects: 0
Study: 1812476

Group type: EXPERIMENTAL
Intervention: Euphylong (once daily at 2000 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional theophylline treatment (twice daily at 800 and 2000 hours)
Number of subjects: 0
Study: 7086761

Group type: EXPERIMENTAL
Intervention: Ampicillin (three-dose perioperative course)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 31893705

Group type: EXPERIMENTAL
Intervention: Matrix-based formulation of the iterative randomized stimulation and averaging (IRSA) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional IRSA method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Least-squares (LS) deconvolution
Number of subjects: 0
Study: 29140440

Group type: EXPERIMENTAL
Intervention: Antenatal behavioral lifestyle intervention (diet and physical activity)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Higher maternal glycemia (specifically fasting glucose at 28 weeks gestation)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Principal component of cord blood phosphatidylcholines and LPCs
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Cord blood insulin growth factor (IGF)-1 and adiponectin concentrations
Number of subjects: 344
Study: 26398674

Group type: EXPERIMENTAL
Intervention: Omeprazole granule
Number of subjects: 34

Group type: COMPARATOR
Intervention: Omeprazole suspension
Number of subjects: 34
Study: 24156664

Group type: EXPERIMENTAL
Intervention: In-home interdisciplinary chronic illness care management intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 22699176

Group type: EXPERIMENTAL
Intervention: Expressive writing program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 19557207

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 534
Study: 17536074

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 162
Study: 15888501

Group type: EXPERIMENTAL
Intervention: Consultant rheumatologist workshops
Number of subjects: 138

Group type: COMPARATOR
Intervention: Nurse clinical educator workshops
Number of subjects: 138
Study: 12572374

Group type: EXPERIMENTAL
Intervention: Huatan Zhuyu Jiedu Decoction (HZJD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Duhuo Jisheng Decoction
Number of subjects: 100
Study: 9448347

Group type: EXPERIMENTAL
Intervention: Bonded and sealed composite restorations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sealed conservative amalgam restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional unsealed amalgam restorations
Number of subjects: 0
Study: 7874943

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2191867

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 133

Group type: COMPARATOR
Intervention: TMP‐SMZ
Number of subjects: 133
Study: 373989

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg for 2 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg for 2 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg for 2 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31984696

Group type: EXPERIMENTAL
Intervention: Symbiotic combination (Lactobacillus and Bifidobacterium with fructo‐ and galacto‐oligosaccharides)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 25
Study: 31593091

Group type: EXPERIMENTAL
Intervention: Mild physical activity intensity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Moderate physical activity intensity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Intense physical activity intensity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Physical activity at work
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Occupational activities
Number of subjects: 252
Study: 27982726

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 12
Study: 25870084

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard advice for diet and exercise (Control)
Number of subjects: 44
Study: 24473536

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (150-μg testosterone patch)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 128
Study: 21885724

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for 1 month
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lifestyle counseling (Control)
Number of subjects: 35
Study: 19672840

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed models (GLMM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models (Bayes-HM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-sample t-test of cluster-level rates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) with empirical covariance estimators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) with model-based covariance estimators
Number of subjects: 0
Study: 17711873

Group type: EXPERIMENTAL
Intervention: Solution-Finding Approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: McKenzie Approach
Number of subjects: 0
Study: 15194332

Group type: EXPERIMENTAL
Intervention: Basiliximab (intravenous bolus injection on day 0 and day 4)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched historical control group (n = 28)
Number of subjects: 28
Study: 11156873

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen plus progestin
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 9158829

Group type: EXPERIMENTAL
Intervention: Plasma bicarbonate concentration
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of free fatty acids (FFA), acetone, and the sum of 3-hydroxybutyrate (3OHB) and lactate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plasma FFA/albumin molar ratio
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Initial anion gap
Number of subjects: 141

Group type: COMPARATOR
Intervention: Plasma glucose and lactate concentrations
Number of subjects: 141
Study: 8480985

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 17
Study: 2434787

Group type: EXPERIMENTAL
Intervention: Ketanserin (5 mg intravenous injections every 4 min, mean total 38 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 20
Study: 31541426

Group type: EXPERIMENTAL
Intervention: 1-day acceptance and commitment therapy (ACT) workshop
Number of subjects: 32
Study: 29581669

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for 4 sessions with 3 day-intervals
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) applied for 10 sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham ESWT for 4 sessions
Number of subjects: 60
Study: 27014804

Group type: EXPERIMENTAL
Intervention: Real PEMF
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham PEMF
Number of subjects: 24
Study: 26341262

Group type: EXPERIMENTAL
Intervention: 2-day use of infusion sets
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4-day use of infusion sets
Number of subjects: 24
Study: 23656530

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) including estradiol alone or in combination with medroxyprogesterone acetate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 20921909

Group type: EXPERIMENTAL
Intervention: Glutamic acid 1.5 grams daily orally in 3 divided doses during the 4-week induction with vincristine (1.5 mg/m² IV weekly)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (oral placebo 3 times daily)
Number of subjects: 94
Study: 18083993

Group type: EXPERIMENTAL
Intervention: P + CI + CL
Number of subjects: 321
Study: 12357041

Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training for 5 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 9793696

Group type: EXPERIMENTAL
Intervention: Migraine without aura (MwoA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MwA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Episodic tension-type headache (ETTH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache (CTTH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Headache-free subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall headache evolution
Number of subjects: 100
Study: 7636936

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 70
Study: 2495916

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally for 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 921864

Group type: EXPERIMENTAL
Intervention: Left lateral tilt during Caesarean section
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right lateral tilt during Caesarean section
Number of subjects: 60
Study: 30419981

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar puncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unassisted lumbar puncture
Number of subjects: 40
Study: 28504358

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy + Management As Usual (FFT + MAU)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Management As Usual (MAU)
Number of subjects: 111
Study: 25597462

Group type: EXPERIMENTAL
Intervention: Conventional pure-tone audiometry (PTA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In-situ audiometry
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resound devices
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phonak, Starkey, and Oticon devices
Number of subjects: 30
Study: 24066729

Group type: EXPERIMENTAL
Intervention: 3Dr
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 3D
Number of subjects: 156

Group type: COMPARATOR
Intervention: 2D+
Number of subjects: 156
Study: 21430252

Group type: EXPERIMENTAL
Intervention: FeSO4 plus ascorbic acid (AA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: NaFeEDTA
Number of subjects: 16
Study: 19396409

Group type: EXPERIMENTAL
Intervention: Trimetazidine (twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 47
Study: 17688458

Group type: EXPERIMENTAL
Intervention: Depot FGAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depot SGAs
Number of subjects: 0
Study: 15235364

Group type: EXPERIMENTAL
Intervention: CRP with mastoid oscillation
Number of subjects: 84

Group type: COMPARATOR
Intervention: CRP alone (nonoscillator group)
Number of subjects: 84
Study: 11854763

Group type: EXPERIMENTAL
Intervention: Flotation-REST technique (experimental group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 9645184

Group type: EXPERIMENTAL
Intervention: Levothyroxine in a weight‐adapted dosage (75, 100 or 150 micrograms) plus 150 micrograms iodide
Number of subjects: 49

Group type: COMPARATOR
Intervention: 100 micrograms levothyroxine plus 100 micrograms iodide
Number of subjects: 49